Genzyme viral contamination reflects gaps in testing program
This article was originally published in The Gold Sheet
Executive Summary
Barry Cherney, director of FDA's Division of Therapeutic Proteins, said that the agency has always realized there were gaps in the control of adventitious agent testing for biologicals, yet the recent Genzyme viral contamination incident, he said, highlighted "even larger gaps.